CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT
ACCEPTANCE OF NEW DRUG APPLICATION FOR DTCP INFANT

This announcement is made by CanSino Biologics Inc. (the "**Company**") on a voluntary basis.

The Company is pleased to announce that the National Medical Products Administration of the People's Republic of China (the "**NMPA**") has recently granted a notice of acceptance to the Company's new drug application for its absorbed diphtheria, tetanus and acellular pertussis (components) combined vaccine (the "**DTcP**") for infants (below 2 years old) (the "**DTcP Infant**") developed by the Company.

The manufacturing process of the co-purified diphtheria, tetanus and acellular pertussis vaccine currently available in China uses a process of co-purification of pertussis antigens. As a diphtheria, tetanus and acellular pertussis (components) vaccine, each pertussis antigen of the DTcP Infant can be purified separately and formulated in a defined ratio, thus ensuring batch-to-batch consistency of product quality and making the product quality more stable.

As of the date of this announcement, no domestically manufactured diphtheria, tetanus and acellular pertussis (components) vaccine has been approved for commercialization in China. The Company's DTcP Infant is positioned as a viable alternative to imported vaccines in China. Furthermore, the development of DTcP Infant establishes the foundation for the further development of the absorbed diphtheria, tetanus and acellular pertussis (components) combined vaccine (for people aged six years old and above), as well as combined vaccine based on the DTcP components. The product portfolio of diphtheria, tetanus and acellular pertussis (components) vaccines will further enrich the Company's product strategy and enhance the Company's core competitiveness.

In the Phase III clinical trial of DTcP Infant, the primary immunization of DTcP Infant starts at the age of 2 months with 3 doses, with an interval of 1 or 2 months between each dose, and the booster immunization is carried out at the age of 18 to 24 months, with each person receiving 1 dose. As of the date of this announcement, the Phase III clinical trial of DTcP Infant is still in progress, and the vaccination and data collection for the primary immunization have been completed, and the Company has obtained the final report of Phase III clinical trial in respect of the primary immunization. Therefore, DTcP Infant possesses the necessary conditions for submitting the new drug application to the NMPA, and the Company will submit the data related to the enhanced immunization of DTcP Infant to the regulatory authorities in due course.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, December 16, 2024

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Shuifa GUI, Mr. Jianzhong LIU and Mr. Yiu Leung Andy CHEUNG as independent non-executive Directors.